This year's J.P. Morgan Healthcare Conference concluded on Thursday, bringing together healthcare leaders from around the world to discuss industry trends and provide updates on their businesses. The event also includes news announcements from companies across the healthcare industry.
Here are six noteworthy announcements made during the event.
—NVIDIA and Eli Lilly and Company Investing US$1 billion Worked at United Innovation Labs in South San Francisco for over five years. The lab will bring together Eli Lilly's biology, chemistry and medical experts with NVIDIA's artificial intelligence engineers to create more powerful models to speed the identification and validation of new drug molecules. The partners said a focus will be on building a “continuous learning system” that connects Eli Lilly's wet labs with computational dry labs so that artificial intelligence can assist researchers around the clock and improve experiments and model development. The laboratory is expected to be operational early this year.
—Novartis Entered into licensing agreement worth nearly $1,000 US$1.7 billion Collaborates with SciNeuro Pharmaceuticals to develop potential antibody therapies for Alzheimer's disease. Novartis has acquired SciNeuro's proprietary technology designed to improve the way antibodies are delivered to the brain, which could differentiate these drug candidates from existing amyloid-targeting therapies. The collaboration will see both companies working together on early-stage development, with Novartis then leading late-stage clinical testing and global commercialization.
—AbbVie Investing $650 million Pre-licensed clinical-stage bispecific cancer drug RC148 from Chinese biotech company Rongchang Technology. The drug is being developed to treat a variety of advanced solid tumors, including lung and colorectal cancer. Under the agreement, AbbVie gains exclusive rights to develop, manufacture and commercialize RC148 outside Greater China. AbbVie's move highlights how global pharmaceutical companies are leveraging Chinese innovation in the crowded but promising field of cancer research and development.
——Generative artificial intelligence startup company Hippocratic Artificial Intelligence Entering the life sciences industry get Agents artificial intelligence specialist Grove AI and creates dedicated life sciences division. Grove's technology facilitates clinical trial operations and helps improve participant participation and recruitment. Hippocrates also appointed a life sciences president and established a life sciences executive advisory board with industry leaders to guide product strategy and implementation.
—vicourta startup selling oncology care software, raises funding $43 million Expand the use of its platform. The company's technology combines clinical data with decision support tools to help clinicians design personalized cancer care plans at the point of care. The company said the funding will accelerate its mission to democratize precision oncology, particularly in community settings where most patients receive treatment.
—Baxter launched new Smart stretcher Designed to improve patient handling and workflow for the care team. The design allows many procedures to be completed without moving the patient, helping to reduce physical stress and injury risk for clinicians. Baxter said stretchers can improve patient safety and operational efficiency in busy hospital environments.
Photo: Richard Drury, Getty Images
